Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02801097 · ClinicalTrials.gov registry record · Phase 1
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
A Phase 1 study, sponsored by EpicentRx.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02801097: Clinical Trial Phase 1 study, sponsored by EpicentRx.
NCT02801097 is a Phase 1 study that was terminated before completion, run by EpicentRx. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02801097, a Phase 1 study, was terminated before completion, sponsored by EpicentRx.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.
Interventions
- DRUG Irinotecan
- DRUG RRx-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 1 |
Why NCT02801097 stopped before completion
NCT02801097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT02801097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02801097 about?
NCT02801097 is a clinical study titled "RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)". This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability...
What is the current status of trial NCT02801097?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-08-30. Estimated completion is 2019-12-09.
What interventions are being tested in trial NCT02801097?
The interventions under investigation include: Irinotecan (DRUG), RRx-001 (DRUG).
Who is sponsoring clinical trial NCT02801097?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02801097's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI